Angina

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

Retrieved on: 
вторник, мая 14, 2024
Security (finance), BCDA, Partnership, Patient, Angina, Arrhythmia, CMS, Medicare, Chest pain, Risk, Heart, Heart failure, THT, FDA, IND, Helix, Therapy, Trial of the century, Hospital, Exercise, Incidence, Mortality, Research, Stroke, Quality of life, Splenic infarction, Pharmaceutical industry

The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.

Key Points: 
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.
  • The interim results from this study, with 110 of the 115 randomized patients, were presented at the Technology and Heart Failure Therapeutics (THT) meeting on March 4, 2024.
  • This study was activated in the first quarter of 2024 with a goal of completing enrollment two years after the first patient is enrolled.
  • First Quarter 2024 Financial Results:
    Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

Retrieved on: 
вторник, мая 14, 2024
Health, Medical Devices, Health Technology, General Health, Radiology, Cardiology, Biotechnology, Patient, Coronary artery disease, Cardiovascular disease, CAD, Angina, Hospital, Chest pain, Risk, Heart, Congress, Diagnosis, Disease, Death, AI, Research, Percutaneous coronary intervention, GE HealthCare, Splenic infarction, PCI, Myocardial infarction, Pulse, Medis, QFR, Physiology, Medical imaging

Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).

Key Points: 
  • Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).
  • The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians.
  • “In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights.
  • Medis’ QFR is a proprietary solution that delivers image-based physiology of coronary obstructions based on angiography imaging analysis alone.

XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions

Retrieved on: 
четверг, мая 2, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Society, University, Phase, Blood, Positron emission tomography, Circulation: Cardiovascular Interventions, Angina, Heart, PET, Disease, Exercise, Gene, Cardiovascular disease, Assistant, Clinical trial, Therapy, SCAI, VEGF, Prevalence, Pharmaceutical industry

XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented final results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy candidate XC001 (encoberminogene rezmadenovec) for refractory angina at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions, May 2-4, 2024 in Long Beach, CA.

Key Points: 
  • XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented final results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy candidate XC001 (encoberminogene rezmadenovec) for refractory angina at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions, May 2-4, 2024 in Long Beach, CA.
  • These encouraging results supporting XC001’s safety and efficacy potential are being simultaneously published in Circulation: Cardiovascular Interventions .
  • XC001 is designed to reduce ischemic burden by creating new blood vessels in the heart through the local expression of multiple vascular endothelial growth factor (VEGF) isoforms.
  • In the Phase 2 portion of the EXACT trial, 32 patients with class II-IV angina were dosed with the maximal dose of XC001 through minimally-invasive transepicardial delivery (direct administration to the heart).

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Retrieved on: 
понедельник, апреля 8, 2024
Observational study, Cardiovascular disease, University Medical Center, Patient, Angina, Șaeș, CCS, American College, University Medical Center Utrecht, DRS, Royal Brompton Hospital, MACE, Pharmaceutical industry

These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.

Key Points: 
  • These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
  • Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
    REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
  • “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
  • Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
вторник, апреля 2, 2024
Depression, Thrombosis, Myocardial infarction, Sudden death, Cardiovascular disease, Exercise, Survival, Coronary artery disease, ECG, Hyperlipidemia, Patient, Palpitations, Angina, Cancer, AI, Death, Moyamoya disease, Chronic pain, Plaque, Diet, Receiver, Smoking, Cardiac catheterization, Stenosis, Oxygen, Heart, Atherosclerosis, Rupture, Ministry, Duke, Vascular occlusion, CAD

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
среда, марта 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
суббота, января 6, 2024
Urinary tract infection, Patient, Medical Subject Headings, Marketing, Agency, Jaw, INN, Interferon beta-1a, Immune system, Fever, Tears, ATC, Disability, Multiple sclerosis, Kidney, Hypertension, International, Blood, RRMS, Attack, Spinal cord, Disease, Headache, Language, Brain, Myocardial infarction, Eye, Heart, Inflammation, Thyroid, Stroke, Head, Angina, European Medicines Agency, Infection, Coagulopathy, Lymphocyte, HIV, Select, Central nervous system, Human, Safety, Anatomy, Checklist, Sclerosis, IIA, Optic nerve, Neck, Rash, CD52, Medical device

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Retrieved on: 
вторник, января 2, 2024
Fungal infection, Medical Subject Headings, Marketing, European Commission, Liver, INN, Nitrate, Woman, Allergy, PDE5, Pelvic floor dysfunction, ATC, Hypotension, Itraconazole, International, Man, European, Headache, Ageing, Language, Blood, CGMP, Mouth, Eye, Pulmonary hypertension, Erectile dysfunction, Stroke, Kidney, Kidney disease, Angina, Ketoconazole, HIV, Ritonavir, Tablet, Indinavir, Select, Committee, Patient, Penis, Liver disease, Risk management, Anatomy, Medicine, Dialysis, IIA, Diabetes, CHMP, Medical device

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Retrieved on: 
вторник, января 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Moyamoya disease, Disease, NYHA, Language, Heart, Death, Angina, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Retrieved on: 
вторник, января 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Anatomy, Medicine, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised